Abstract
The situation created after the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and compulsory licensing may have an impact on pharmaceutical multinational corporations (MNCs) patent filing trend in India. So, there is a need to understand the impact of intellectual property (IP) policy change in the patenting trend of pharmaceutical MNCs in India. There are no studies on the patenting trend of pharmaceutical MNCs in India specifically to their disclosed treatable diseases and product and process patent types. This study is based on patinformatics and information analysis, to establish the implications of Indian IP policy on patenting activity of pharmaceutical MNCs in India. This study correlates pre and post TRIPS patenting trend of pharmaceutical MNCs in India. This study finds that after an amendment of Indian Patent Act in compliance with TRIPS norms, MNCs have filed a number of patents in India. This study concludes that Indian pharmaceutical companies can devise the RD this will give them a competitive edge over the global players.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
